Source:http://linkedlifedata.com/resource/pubmed/id/12199784
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2002-8-29
|
| pubmed:abstractText |
In attempting to restore the chronic phase (CP) of chronic myelogenous leukaemia (CML), the Swedish CML group utilized an intensive chemotherapy protocol for 83 patients (aged 16-79 years) in accelerated (AP, n = 22) or blastic phase (BC, n = 61). Most patients received a combination of mitoxantrone (12 mg/m2/d) and etoposide (100 mg/m2/d) together with cytosine arabinoside (1 g/m2 b.i.d) for 4 d. Overall, 39 patients (47%) achieved a second CP (CP2)/partial remission (PR). Responding patients < 65 years were eligible for ablative chemotherapy followed by an allogeneic (SCT) or a double autologous stem cell transplant (ASCT). Seventeen of 34 responders < 65 years failed to proceed to transplantation as a result of early disease progression (n = 15) or disease-related complications (n = 2). The remaining 17 patients underwent SCT (n = 9; including four unrelated donor SCT) or ASCT (n = 8). Only one of the eight ASCT patients had a second ASCT; the remaining seven failed because of progression (n = 5) or hypoplasia (n = 2). The median duration of CP2/PR was 6 months (range 1-72 months). Five patients achieved a longer CP2/PR than CP1. The 1 year survival was 70% for SCT/ASCT patients (median survival 21 months), 50% for responding patients overall, but only 7% for non-responders (P < 0.001). Three SCT/ASCT patients are long-term survivors (65+, 66+ and 73+ months). In conclusion, approximately half of the patients achieved a CP2/PR after intensive chemotherapy, with a clear survival advantage for responders vs non-responders. Subsequent SCT/ASCT was feasible for half of the responders (< 65 years), and one individual underwent double ASCT. Novel therapeutic options for CML patients in AP/BP are needed.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0007-1048
|
| pubmed:author |
pubmed-author:AxdorphUllaU,
pubmed-author:BjörkholmMagnusM,
pubmed-author:CarneskogJanJ,
pubmed-author:GrimforsGunnarG,
pubmed-author:HansenJanJ,
pubmed-author:LöfvenbergEvaE,
pubmed-author:LinderOlleO,
pubmed-author:LjungmanPerP,
pubmed-author:MalmClaesC,
pubmed-author:SimonssonBengtB,
pubmed-author:StenkeLeifL,
pubmed-author:Swedish CML Group,
pubmed-author:TuressonIngemarI,
pubmed-author:UdénAnne-MarieAM,
pubmed-author:VilénLarsL
|
| pubmed:issnType |
Print
|
| pubmed:volume |
118
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1048-54
|
| pubmed:dateRevised |
2009-6-29
|
| pubmed:meshHeading |
pubmed-meshheading:12199784-Adolescent,
pubmed-meshheading:12199784-Adult,
pubmed-meshheading:12199784-Aged,
pubmed-meshheading:12199784-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12199784-Blast Crisis,
pubmed-meshheading:12199784-Combined Modality Therapy,
pubmed-meshheading:12199784-Cytarabine,
pubmed-meshheading:12199784-Etoposide,
pubmed-meshheading:12199784-Female,
pubmed-meshheading:12199784-Humans,
pubmed-meshheading:12199784-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:12199784-Male,
pubmed-meshheading:12199784-Middle Aged,
pubmed-meshheading:12199784-Mitoxantrone,
pubmed-meshheading:12199784-Prognosis,
pubmed-meshheading:12199784-Remission Induction,
pubmed-meshheading:12199784-Statistics, Nonparametric,
pubmed-meshheading:12199784-Stem Cell Transplantation,
pubmed-meshheading:12199784-Survival Rate
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.
|
| pubmed:affiliation |
Division of Haematology, Department of Medicine, Karolinska Hospital and Institutet, Stockholm, Sweden.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|